To The Moon

"Recycled" headlines are being weaponized by short sellers to drive the price down, despite the facts being largely known. ​$Hims & Hers Health Inc.(HIMS)$   Status: Bearish (Artificial Pressure) ​1. The Short Seller's Playbook ​It’s clear that someone is trying to push the share price lower by circulating "stale" news. The headlines about Amazon’s push into GLP-1 and Eli Lilly’s Foundayo aren’t fundamentally new, but they are being timed to hit the tape while the stock is vulnerable. ​The Goal: Trigger stop-losses and panic selling among retail investors who may have missed the original news cycle in 2025. ​The Weapon: Amazon's $149/month price point for branded oral pills. While Hims already knew this was coming, seeing it operatio

Avis Budget Group just pulled off something that shouldn’t be possible. A company buried under $25B in debt just went vertical — +600% in a month, smashing all-time highs at $608.80 after a +23% single-day surge. $Avis Budget(CAR)$   Read that again. Now here’s where reality starts to glitch: Two hedge funds — SRS Investment Management and Pentwater Capital Management — quietly control 71% of the shares. But it gets crazier. Once you include their cash-settled equity swaps, their effective exposure goes over 100% of the entire float. Yes — more claims than actual shares in existence. Meanwhile, the company itself? – Burned $995M – Crushed under massive debt – Fundamentals deteriorating for months And the market said: doesn’t matter. Because th

Jim Cramer once claimed Microsoft had the weakest AI business and called Copilot “ridiculous.” Meanwhile, smart money was accumulating below $400. $Microsoft(MSFT)$   $Amazon.com(AMZN)$   $Alphabet(GOOG)$   $Oracle(ORCL)$   This is the gap between narrative and reality. A lot of commentary—especially from traditional finance and media—lacks real depth in AI. It focuses on what already happened, not what’s structurally coming next. Some YouTuber even prioritize pushing subscriptions or so-called custom-made software. Here’s what’s being underestimated:

True happiness isn’t always perched high above the city in a sleek rooftop bar. More often, it’s louder, sweatier, and far more satisfying. At Old Airport Road Food Centre, joy comes served hot on a plate filled with heritage, flavor, and familiarity. The Anatomy of a Perfect Meal Happiness here is a table overflowing with Singapore’s greatest hits. It’s the visual (and edible) contrast of: The Golden Standard: A plate of Hokkien Mee—rich, silky gravy coating springy noodles, topped with bright prawns and finished with a squeeze of lime to cut through the depth. The Charred Comfort: A generous serving of Black Carrot Cake, caramelized in dark soy sauce, layered with the salty crunch of chai poh and the smoky aroma of egg kissed by the wok. The Modern Twist: A bowl of scrambled egg cut

In 2001, a gutsy engineer, Mark Wang in Kaohsiung, Taiwan, started WinWay Technology with just NT$2 million (~$60,000 USD) and a wild vision. For the first six years, it was literally a one-man operation running from a home office — almost zero orders, pure grind. Fast forward to 2026: The founder’s stake is now worth well over NT$40 billion (~$1.25 billion+). The company’s market cap has exploded past NT$350–370 billion, and the stock (6515.TW) has delivered over 1,000% returns in the past year, trading near all-time highs around NT$9,800–10,300 after a staggering 260%+ YTD surge. This isn’t luck. It’s one of the smartest high-stakes bets in the semiconductor supply chain. Breaking the Plastic Ceiling — Before AI Even Had a Name Back when the industry was happy with cheap plasti

Section 1: The Rise and Fall of Sentiment In this article, I’ll outline why I see $Hims & Hers Health Inc.(HIMS)$   as a significant opportunity for both short-term gains and long-term growth. To grasp the full scope of this opportunity, we have to look back to mid-Q4 2025. On October 15th, the company announced that its Hers brand would enter the menopause treatment market—a massive, underserved sector. Investors cheered, sending the stock soaring toward $65. At the height of the frenzy, CEO Andrew Dudum even fueled the fire by reposting a comment that read, “Let the short squeeze begin.” However, that peak was short-lived. The following day, the stock slid 8%. Sentiment soured further when news broke

I’m seeing a guy trying to lure people into his Telegram by posting “trade alerts” from Tiger Brokers. Problem is… the screenshots look backdated. Anyone can edit timestamps and make it look like they called the move. And somehow he’s built ~2.5k followers. That’s the surprising part. Just be careful — it’s easy to fake wins, hard to verify real performance. As for me, I just share my lifestyle and whatever research I’m doing — free, no subscriptions, no paywall. Along the way, I’ve made both good calls and bad ones. There’s no such thing as 100% accuracy in the market. If someone claims that, you should question it. Stay realistic — that’s where consistency comes from.

Making millions in the market is possible. But only with conviction and a deep understanding of the company thesis. Most people sold when $Hims & Hers Health Inc.(HIMS)$   crashed. I didn’t. Here’s what changed since the lows — and why I’m still allocating: 1. *De-risking:* $NVO partnership removes a major overhang 2. *Expansion:* Aggressive global M&A building the DTC engine 3. *Category tailwind:* Peptides are going mainstream, and $HIMS is positioned as the distribution layer 4. *Macro shift:* Fed likely turns dovish after President Trump nominated Kevin Warsh 5. *Geopolitics:* Iran war likely to end soon, backdrop turning friendlier 6. *Consumer boost:* Oil price tanking supports discretionary s

HIMS Is Quietly Building a Category Most People Don’t Understand $Hims & Hers Health Inc.(HIMS)$  might be sitting on its biggest catalyst yet — but the market hasn’t fully connected the dots. If the U.S. Food and Drug Administration actually follows through on reevaluating restricted peptides (as hinted by Robert F. Kennedy Jr.), this could quietly unlock a massive new market. Peptides are booming in the US ! HIMS distribution and social could be a massive upside here. You must have conviction ! Peptides are short chains of two or more amino acids linked by covalent (peptide) bonds, acting as fundamental building blocks for proteins and serving as crucial cell-signaling molecules. They are generally sm

Oracle Corporation $Oracle(ORCL)$  just ripped +12% in ONE DAY — and no, this isn’t just a random bounce. This is what people are missing 👇 ⚡ Not Just a Rebound — It’s a SIGNAL Yes, the stock was beaten down -30% YTD. Yes, it was oversold. But this move? This wasn’t technical. This was conviction coming back. 🧠 AI Is No Longer a Story — It’s EXECUTION In ONE DAY, Oracle dropped multiple bombs: Upgraded AI-powered industry platforms Expanded cloud infrastructure globally (Morocco region) Pushed deeper into enterprise AI applications (Fusion AI agents) This is no longer “we plan to do AI.” 👉 This is “we are building it at scale.” 💰 The $14 BILLION CONFIDENCE CHECK Wall Street doesn’t hand out $14B for fun. Backed